IRELAND’S HSE APPROVES LILLY’S ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY FOR ADJUVANT TREATMENT OF PEOPLE WITH HR+, HER2- EARLY BREAST CANCER AT HIGH-RISK OF RECURRENCE

IRELAND’S HSE APPROVES LILLY’S ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY FOR ADJUVANT TREATMENT OF PEOPLE WITH HR+, HER2- EARLY BREAST CANCER AT HIGH-RISK OF RECURRENCE

Abemaciclib in combination with endocrine therapy is the first CDK4/6 inhibitor to be made available in Ireland from 01 June, 2024 following approval for reimbursement from the Health Service Executive (HSE) for people with HR+, HER2-, nodepositive early breast cancer at high-risk of recurrence 1,2